Condition
Cardiomyopathy, Secondary
Total Trials
4
Recruiting
1
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting2
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07721025Phase 2Recruiting
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
NCT07276139Active Not RecruitingPrimary
PACEVALUE: Development of a Risk Score to Predict Pacing-Induced Cardiomyopathy in Patients Undergoing Pacemaker or ICD Implantation and Evaluation of Patient Outcomes and Cost-Effectiveness Across Different Healthcare Systems
NCT05445323Phase 1Active Not Recruiting
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
NCT02960256Completed
The Impact of Infectious Disease on QT Segment
Showing all 4 trials